A Comparison of Lipids and apoB in Asian Indians and Americans.
India
United States
apolipoprotein B
atherosclerotic vascular disease
dyslipidemia
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
20 01 2021
20 01 2021
Historique:
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Apolipoprotein B (apoB) integrates and extends the information from the conventional measures of atherogenic cholesterol and triglyceride. To illustrate how apoB could simplify and improve the management of dyslipoproteinemia, we compared conventional lipid markers and apoB in a sample of Americans and Asian Indians. Data from the US National Health and Nutrition Examination Survey (NHANES) (11,778 participants, 2009-2010, 2011-2012), and the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) cohort study in Delhi, India (4244 participants), 2011 were evaluated. We compared means and distributions of plasma lipids, and apo B using the Mann-Whitney U test and Fisher's exact test. A p value of < 0.05 was considered significant. The plasma lipid profile differed between Asian Indians and Americans. Plasma triglycerides were greater, but HDL-C lower in Asian Indians than in Americans. By contrast, total cholesterol, non-HDL-C, and LDL-C were all significantly higher in Americans than Asian Indians. However, apoB was significantly higher in Asian Indians than Americans. The LDL-C/apoB ratio and the non-HDL-C/apoB ratio were both significantly lower in Asian Indians than Americans. Whether Americans or Asian Indians are at higher risk from apoB lipoproteins cannot be determined based on their lipid levels because the information from lipids cannot be integrated. ApoB, however, integrates and extends the information from triglycerides and cholesterol. Replacing the conventional lipid panel with apoB for routine follow ups could simultaneously simplify and improve clinical care.
Sections du résumé
Background and aims
Apolipoprotein B (apoB) integrates and extends the information from the conventional measures of atherogenic cholesterol and triglyceride. To illustrate how apoB could simplify and improve the management of dyslipoproteinemia, we compared conventional lipid markers and apoB in a sample of Americans and Asian Indians.
Methods
Data from the US National Health and Nutrition Examination Survey (NHANES) (11,778 participants, 2009-2010, 2011-2012), and the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) cohort study in Delhi, India (4244 participants), 2011 were evaluated. We compared means and distributions of plasma lipids, and apo B using the Mann-Whitney U test and Fisher's exact test. A p value of < 0.05 was considered significant.
Results
The plasma lipid profile differed between Asian Indians and Americans. Plasma triglycerides were greater, but HDL-C lower in Asian Indians than in Americans. By contrast, total cholesterol, non-HDL-C, and LDL-C were all significantly higher in Americans than Asian Indians. However, apoB was significantly higher in Asian Indians than Americans. The LDL-C/apoB ratio and the non-HDL-C/apoB ratio were both significantly lower in Asian Indians than Americans.
Conclusion
Whether Americans or Asian Indians are at higher risk from apoB lipoproteins cannot be determined based on their lipid levels because the information from lipids cannot be integrated. ApoB, however, integrates and extends the information from triglycerides and cholesterol. Replacing the conventional lipid panel with apoB for routine follow ups could simultaneously simplify and improve clinical care.
Identifiants
pubmed: 33598387
doi: 10.5334/gh.882
pmc: PMC7824978
doi:
Substances chimiques
Apolipoproteins B
0
Cholesterol, HDL
0
Lipids
0
Triglycerides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Subventions
Organisme : FIC NIH HHS
ID : K43 TW011164
Pays : United States
Informations de copyright
Copyright: © 2021 The Author(s).
Déclaration de conflit d'intérêts
All authors (KS, LD, AN, KMVN, NT, AS, DP) declare that they have no conflicts of interest to disclose. GT: Dr. Thanassoulis reports grants from Ionis Pharmaceuticals and Servier Canada, personal fees (consulant/advisory boards) from Ionis, Servier Canada, Amgen, Sanofi, Novartis, Silence and HLS therapeutics.
Références
Circulation. 2014 Feb 4;129(5):553-61
pubmed: 24345402
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711
pubmed: 28183512
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Eur Heart J. 2013 Jun;34(24):1826-33
pubmed: 23248205
J Clin Lipidol. 2011 Mar-Apr;5(2):105-13
pubmed: 21392724
Circulation. 2009 Feb 24;119(7):931-9
pubmed: 19204302
Eur Heart J. 2018 Apr 7;39(14):1131-1143
pubmed: 29045644
BMC Public Health. 2012 Aug 28;12:701
pubmed: 22928740
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
pubmed: 21487090
Curr Atheroscler Rep. 2014 Sep;16(9):440
pubmed: 25079293
Atherosclerosis. 2020 Feb;294:10-15
pubmed: 31931463
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
JAMA. 2017 Sep 12;318(10):947-956
pubmed: 28846118
Am J Cardiol. 2003 May 15;91(10):1173-7
pubmed: 12745098
J Lipid Res. 1988 Nov;29(11):1461-73
pubmed: 3241122
Nat Genet. 2013 Nov;45(11):1345-52
pubmed: 24097064
Circulation. 2018 Jul 17;138(3):244-254
pubmed: 29506984
J Clin Lipidol. 2007 Dec;1(6):583-92
pubmed: 19657464
Circulation. 2015 Mar 3;131(9):774-85
pubmed: 25573147
Am J Cardiol. 2012 Nov 15;110(10):1468-76
pubmed: 22906895
Clin Chem. 2013 May;59(5):752-70
pubmed: 23386699
Atherosclerosis. 2012 Dec;225(2):444-9
pubmed: 23068583
Eur J Prev Cardiol. 2020 Aug;27(12):1255-1268
pubmed: 31475865
Clin Chem. 1994 Apr;40(4):586-92
pubmed: 8149615
J Am Heart Assoc. 2020 Sep 15;9(18):e014711
pubmed: 32892691
J Am Heart Assoc. 2014 Apr 14;3(2):e000759
pubmed: 24732920
PLoS Med. 2020 Mar 23;17(3):e1003062
pubmed: 32203549
J Lipid Res. 2018 Jul;59(7):1266-1275
pubmed: 29769239
Int J Epidemiol. 2020 Nov 01;:
pubmed: 33130851
J Am Coll Cardiol. 2016 Jan 19;67(2):193-201
pubmed: 26791067
Circulation. 2016 Apr 19;133(16):1605-20
pubmed: 27142605
Curr Opin Lipidol. 2016 Oct;27(5):473-83
pubmed: 27472409
JAMA Cardiol. 2019 Dec 1;4(12):1287-1295
pubmed: 31642874
Clin Chem. 2018 Jul;64(7):1006-1033
pubmed: 29760220
Eur J Prev Cardiol. 2015 Oct;22(10):1321-7
pubmed: 25633587
Clin Chem. 2017 Apr;63(4):870-879
pubmed: 28174174
JAMA. 2019 Jan 29;321(4):364-373
pubmed: 30694319